case_images: PMC10704348_01
case_images: Time course and cerebral imaging. (A) Timeline showing clinical, diagnostic and therapeutic developments. (B) Cerebral MRI scans at different time points. Upper panels: T2 fluid-attenuated inversion recovery (FLAIR)-weighted image, lower panels: T1-weighted image with contrast enhancement. MRI n 2 shows multiple new and contrast-enhancing lesions (arrows).
case_images: fonc-13-1303141-g001.jpg
case_images: PMC10704348_01_fonc-13-1303141-g001.jpg
case_images: f1
case_images: In December 2021, a routine MRI scan showed an exacerbation of radiological disease activity with ten new and gadolinium-enhancing lesions ( Figure 1B ). In an MRI scan in January 2023 ( Figure 1B ), no new MS lesions were observed.
case_images: Flow cytometric analysis pre- and post-ocrelizumab (OCR) treatment. (A) Activation markers PD-1 and KLRG1 are elevated on CSF compared to peripheral blood CD4+ T cells at baseline. (B) Six months after ocrelizumab treatment, CD45RO+CCR6+ Th17 cells are reduced compared to baseline. (C) Levels of B cells are reduced under ocrelizumab treatment. (D) Ocrelizumab changes B cell subset composition, with decrease of IgD+CD27+ non-switched memory B cells and proportional increase of CD38++CD24++ transitional B cells and CD38++CD24- plasmablasts.
case_images: fonc-13-1303141-g002.jpg
case_images: PMC10704348_01_fonc-13-1303141-g002.jpg
case_images: f2
case_images: CSF ( Figure 2 ). CD4+ T cells composed the largest fraction of lymphocytes (PBMC: 58.9%; CSF: 78.9%) followed by CD8+ T cells (PBMC: 14.1%; CSF: 13.0%) and B cells (PBMC: 4.69%; CSF: 1.6%).